Trust in medical researchers has fallen significantly in recent years, and at least one company thinks paying study participants might be part of the solution.
Gillette is testing a model in which people who take part in medical research studies receive direct financial compensation, according to a report by the Star Tribune. The move comes as surveys and studies have shown a sharp drop in public confidence in medical research institutions, a trend that accelerated during and after the COVID-19 pandemic.
Recruiting enough participants has long been a challenge in clinical and medical research. Studies often run behind schedule or produce less reliable results when they cannot attract a representative sample of the population. Researchers have debated for years whether paying subjects improves participation rates and whether it introduces ethical complications around consent and coercion.
Proponents of paying participants argue that compensation respects the time and inconvenience that study subjects take on and may help bring in more diverse groups of people who might otherwise be unable to volunteer. Critics have raised concerns that financial incentives could lead some people to participate even when it may not be in their best interest, or could draw participants who underreport health conditions to qualify.
The decline in public trust has added a new dimension to the recruitment problem. When people do not believe researchers have their interests at heart, they are less likely to volunteer for studies regardless of what is offered. Gillette's approach appears aimed at both the practical and the perception problem, signaling to potential participants that their involvement has real value.
The Star Tribune report did not specify what types of studies Gillette is funding or what compensation amounts are being offered to participants. It also was not clear how the company plans to measure whether the payment model successfully improves either participation rates or trust levels over time.
The broader question of how to restore public confidence in medical research remains unresolved. Institutions including universities, federal health agencies, and pharmaceutical companies have all faced increased skepticism from the public in recent years, and no single approach has emerged as a clear answer.
